GlassScriptPhysician profile
Sana Javaid
NPI 1104592880
$3,030.31
in general payments reported to CMS, 2019-2025
21 companies · $583 in 2025
The $583 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.37 · 2022: $425 · 2023: $340 · 2024: $1,618 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,651 · Consulting Fee: $800 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,650.70 |
| Consulting Fee | $800.00 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,164.08 | 2021-2025 | |
| Eisai INC. | $292.12 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $193.54 | 2024-2025 | |
| Abbvie INC. | $176.88 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $152.54 | 2022-2025 | Onivyde, Somatuline Depot |
| Daiichi Sankyo INC. | $145.82 | 2022-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $113.95 | 2021-2023 | |
| Taiho Oncology, INC. | $110.59 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $99.77 | 2022-2024 | Keytruda |
| Exelixis INC. | $94.96 | 2025 | Cabometyx |
| Incyte Corporation | $89.99 | 2024 | |
| Tersera Therapeutics LLC | $77.98 | 2024 | Xermelo |
| Foundation Medicine, INC. | $69.40 | 2022-2023 | Foundationone Liquid Cdx |
| Takeda Pharmaceuticals U.S.A., INC. | $66.29 | 2023-2025 | Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $59.49 | 2023 | Opdivo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.62 | 2023 | Lumakras |
| Myovant Sciences INC. | $24.07 | 2022 | |
| Lilly USA, LLC | $20.55 | 2021 | |
| Seagen INC. | $19.43 | 2022 | |
| Spectrum Pharmaceuticals INC. | $18.35 | 2024 | Rolvedon |
| Regeneron Healthcare Solutions, INC. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sana Javaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.